 |
市場調查報告書
商品編碼
2041523
全球分子傳染病檢查市場（至 2031 年）：按產品和服務（試劑盒和設備）、類型（單重和多重）、檢測類型（實驗室和即時檢測）、疾病（性行為感染感染、流感、胃腸病、院內感染）、技術（PCR 和 NGS）以及最終用戶（診斷實驗室和醫院）分類Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2031 |
||||||
價格
預計到 2031 年，分子傳染病檢查的市場規模將達到 190.9 億美元，高於 2026 年的 113 億美元，預計成長率為 11.1%。
| 調查範圍 | |
|---|---|
| 調查期 | 2024-2031 |
| 基準年 | 2025 |
| 預測期 | 2026-2031 |
| 單元 | 金額（美元） |
| 部分 | 產品/服務、類型、測試類型、疾病、技術、最終用戶 |
| 目標區域 | 北美、歐洲、亞太地區、拉丁美洲、中東和非洲、海灣合作理事會國家 |
分子診斷技術的快速發展是推動該市場成長的主要動力。 PCR和次世代定序等創新技術提高了檢測的準確性、速度和效率，使其更加經濟實惠且應用廣泛。
此外，參與企業正在不斷開發先進的自動化診斷系統。這將有助於更準確、更快速地檢測感染疾病，從而改善患者預後並加強對新興病原體的監測。因此，醫療服務提供者可以就分子診斷在感染疾病中的應用做出更明智的決策。
“按檢測類型分類，預計臨床檢測領域在預測期內將呈現最高的成長率。”
臨床檢測領域成長最為迅速，這主要得益於其在檢測多種病原體方面的高準確性和高效率。包括PCR和定序在內的臨床檢測在醫院和診斷實驗室中特別普及，因為它們能夠準確識別疾病。實驗室自動化和高通量系統的顯著進步進一步提高了這些檢測的效率。此外，對能夠一次檢測多種感染疾病的綜合診斷檢測的需求日益成長，也進一步增強了人們對實驗室檢測的偏好。憑藉可靠的結果和強大的診斷能力，實驗室檢測為感染疾病提供了有效的解決方案。
“按類型分類，多重檢測領域將在 2025 年佔據最大的市場佔有率。”
多重檢測技術能夠同時進行多種檢測，透過一次檢測即可檢測和區分多種病原體，進而推動市場發展。這項技術不僅節省時間、成本和精力，也使其成為醫療專業人員的理想選擇。此外，合併感染的日益普遍、對全面診斷檢測的需求以及對更短時間內獲得更準確結果的要求，都促進了多重檢測市場的成長。
“從區域來看，預計亞太地區在預測期內將經歷最快的成長。”
尤其是在亞太地區，受人口稠密地區感染疾病高發的推動，該市場正經歷顯著成長。對疾病早期檢測的日益重視，推動了對先進診斷工具的需求。各國政府和醫療機構正大力投資，加強醫療基礎建設，改善診斷設施，並支持相關研究舉措。此外，對疾病監測和集體爆發管理的日益重視，以及不斷成長的醫療支出，都促使亞太地區在分子傳染病檢查市場的整體成長中扮演著重要角色。
本報告考察了全球分子傳染病檢查市場，提供了市場概述、影響市場成長的各種因素分析、技術和專利趨勢、法律制度、案例研究、歷史和預測市場規模、按各個細分市場和地區/主要國家進行的詳細分析、競爭格局以及主要公司的概況。
目錄
第1章：引言
第2章執行摘要
第3章重要考察
第4章 市場概覽
- 市場動態
- 促進因素
- 抑制因子
- 機會
- 任務
- 未滿足的需求和閒置頻段
- 與相關市場和不同產業相關的跨領域機遇
- 一級/二級/三級公司的策略性舉措
第5章 產業趨勢
- 波特五力分析
- 總體經濟指標
- GDP趨勢與預測
- 供應鏈分析
- 價值鏈分析
- 生態系分析
- 價格分析
- 貿易分析
- 2026-2027 年主要會議和活動
- 影響我們客戶公司業務的趨勢/顛覆性因素
- 投資和資金籌措場景
- 2025年美國關稅對分子傳染病檢查市場的影響
第6章：技術進步、人工智慧的影響、專利、創新與未來應用
- 主要新興技術
- 次世代定序
- 聚合酵素鏈鎖反應
- 互補技術
- 生物資訊學和數據分析平台
- 臨床實驗室資訊系統 (LIS) 和數位健康整合
- 鄰近技術
- 基於CRISPR的診斷
- 數位PCR（DPCR）
- 技術/產品藍圖
- 專利分析
- 未來應用
- 人工智慧/生成式人工智慧對分子傳染病檢查市場的影響
第7章永續性和監管情勢
- 當地法規和合規性
- 對永續性的承諾
第8章：顧客趨勢與購買行為
- 決策流程
- 相關人員及購買評估標準
- 實施障礙和內部挑戰
- 各個終端用戶產業尚未滿足的需求
- 市場盈利
第9章 分子傳染病檢查市場：依產品及服務分類
- 試劑和試劑盒
- 裝置
- 軟體與服務
第10章 分子傳染病檢查市場：依類型分類
- 多重測試
- 單重檢測
第11章 分子傳染病檢查市場：依檢測類型分類
- 實驗室檢測
- 就地檢驗
第12章 分子傳染病檢查市場：依疾病分類
- 呼吸道感染疾病
- 流感
- 結核
- 咽頭炎
- 非結核分枝桿菌（NTM）肺部感染疾病
- 其他
- 胃腸道感染疾病
- 肝炎
- 其他
- 性行為感染傳染病
- 人類免疫力缺乏病毒
- 人類乳突病毒
- 披衣菌感染衣原體
- 淋病
- 梅毒
- 其他
- 院內感染
- 陰道炎
- 腦膜炎
- 透過媒介動物傳播的疾病
- 血液感染疾病和敗血症
- 其他感染疾病
第13章：分子傳染病檢查市場：依技術分類
- 聚合酵素鏈鎖反應
- 恒溫核酸增幅技術
- DNA定序與次世代定序
- 原位雜合反應
- DNA微陣列
- 其他技術
第14章 分子傳染病檢查市場：依最終用戶分類
- 診斷實驗室
- 醫院和診所
- 其他
第15章 分子傳染病檢查市場：依地區分類
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 俄羅斯
- 西班牙
- 其他
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 其他
- 拉丁美洲
- 巴西
- 墨西哥
- 其他
- 中東和非洲
- 海灣合作理事會國家
第16章 競爭格局
- 主要參與企業的策略/優勢
- 收入分析
- 市佔率分析
- 企業估值矩陣：主要公司
- 公司估值矩陣：新創企業/中小企業
- 企業估值和財務指標
- 品牌/產品對比
- 競爭格局
第17章：公司簡介
- 大公司
- DANAHER
- F. HOFFMANN-LA ROCHE LTD.
- BIOMERIEUX
- HOLOGIC, INC.
- ABBOTT
- THERMO FISHER SCIENTIFIC INC.
- QIAGEN
- REVVITY
- GRIFOLS, SA
- SEEGENE INC.
- DIASORIN SPA
- SIEMENS HEALTHINEERS AG
- BECTON, DICKINSON AND COMPANY (BD)
- SD BIOSENSOR
- 其他公司
- QUIDELORTHO CORPORATION
- BRUKER
- GENETIC SIGNATURES
- CO-DIAGNOSTICS, INC.
- VELA DIAGNOSTICS
- MOLBIO DIAGNOSTICS PVT. LTD.
- SAVYON DIAGNOSTICS
- UNIOGEN OY
- GENEOMBIO TECHNOLOGIES
- ADVANCED MOLECULAR DIAGNOSTICS
- ALTONA DIAGNOSTICS GMBH
- GENEFIRST LIMITED
第18章：調查方法
第19章附錄
Product Code: MD 9285
The market for molecular infectious disease testing is expected to grow from USD 11.30 billion in 2026 to reach USD 19.09 billion by 2031, at a growth rate of 11.1%.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product & Service, Type, Test Type, Disease, Technology, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries |
The rapid advancement of molecular diagnostic techniques is a key driver of this market's growth. Innovations such as PCR and next-generation sequencing enhance the accuracy, speed, and efficiency of tests, making them more affordable and widely accessible.
Furthermore, companies in the market are continuously developing advanced automated diagnostic systems. This leads to more precise and rapid detection of infectious diseases, resulting in improved patient outcomes and better monitoring of emerging pathogens. Consequently, healthcare providers can make more informed decisions regarding the application of molecular diagnostics for infectious diseases.
"The laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period."
The market for molecular infectious disease testing can be divided into two main categories: laboratory tests and point-of-care tests, depending on the type of test. The laboratory tests segment is the fastest-growing due to its high accuracy and efficiency, as these tests can detect a wide range of pathogens. Laboratory tests, including PCR testing and sequencing-based testing, are particularly popular among hospitals and diagnostic laboratories because they provide precise disease identification. Significant advances in lab automation and high-throughput systems have enabled these tests to be performed efficiently. Additionally, there is a growing demand for comprehensive diagnostic tests that can detect multiple infections in a single test, further enhancing the preference for laboratory testing. With their reliable results and high diagnostic capabilities, laboratory tests offer an effective solution for detecting infectious diseases.
"The multiplex testing segment accounted for the largest market share, by type, in 2025."
The global market for molecular infectious disease testing can be divided into two main segments: singleplex testing and multiplex testing. Among these, multiplex testing leads the market due to its ability to run multiple tests simultaneously, enabling the detection and differentiation of various pathogens in a single test. This capability not only saves time, money, and effort but also makes it the preferred choice for healthcare providers. Additionally, the rise in co-infections, the need for comprehensive diagnostic tests, and the demand for accurate results in shorter timeframes have all contributed to the growth of the multiplex testing market.
"The Asia Pacific is the fastest-growing market for molecular infectious disease testing during the forecast period."
The global market for molecular infectious disease testing is segmented into the following regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries. The market is experiencing significant growth, particularly in the Asia Pacific region, driven by the high prevalence of infectious diseases in densely populated areas. There is a growing emphasis on early disease detection, which increases the demand for advanced diagnostic tools. Government and healthcare organizations are making substantial investments to enhance healthcare infrastructure, improve diagnostic facilities, and support research initiatives. Additionally, a focus on disease surveillance, outbreak management, and increased healthcare expenditure further contributes to the Asia Pacific region's significant role in the overall growth of the molecular infectious disease testing market.
The breakdown of the profile of primary participants in the molecular infectious disease testing market is:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
- By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
The key players in the molecular infectious disease testing market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).
Research Coverage:
This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point-of-care tests), by disease [respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector-borne diseases, hospital-acquired infections, and other infectious diseases], by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the molecular infectious disease testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. This report covers the competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem.
Reasons to buy this report:
The report will provide market leaders and newcomers with valuable insights into the revenue figures for the overall molecular infectious disease testing market and its subsegments. It will help stakeholders comprehend the competitive landscape, enabling them to better position their businesses and formulate effective go-to-market strategies. Additionally, the report will offer insights into the current market dynamics, highlighting key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (growing global infectious disease burden, advancements in molecular diagnostic technologies, growing funding for molecular testing, and growing awareness of early disease detection), restraints (lack of standardized reimbursement structures and high cost of instruments and consumables), opportunities (expansion potential across emerging economies, rising demand for point-of-care (POC) testing), and challenges (stringent and varying regulatory requirements, operational barriers and labor shortage challenges, and supply chain disruptions for reagents and kits) influencing the growth of the molecular infectious disease testing market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the molecular infectious disease testing market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Hologic, Inc. (US), and Abbott (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW
- 3.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
- 3.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2026 VS. 2031
- 3.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2026 VS. 2031
- 3.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2026 VS. 2031
- 3.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031
- 3.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2026 VS. 2031
- 3.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Growing global infectious disease burden
- 4.2.1.2 Advancements in molecular diagnostic technologies
- 4.2.1.3 Growing funding for molecular testing
- 4.2.1.4 Growing awareness of early disease detection
- 4.2.2 RESTRAINTS
- 4.2.2.1 Lack of standardized reimbursement structures
- 4.2.2.2 High cost of instruments and consumables
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Expansion potential across emerging economies
- 4.2.3.2 Rising demand for point-of-care (POC) testing
- 4.2.4 CHALLENGES
- 4.2.4.1 Stringent and varying regulatory requirements
- 4.2.4.2 Operational barriers and labor shortage challenges
- 4.2.4.3 Supply chain disruptions for reagents and kits
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS & WHITE SPACES
- 4.3.1 UNMET NEEDS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
- 4.5.1 KEY MOVES & STRATEGIC FOCUS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS & FORECAST
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024-2026
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 3822)
- 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES & EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.10 INVESTMENT & FUNDING SCENARIO
- 5.11 IMPACT OF 2025 US TARIFFS ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON REGIONS
- 5.11.4.1 North America
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END-USE INDUSTRIES
- 5.11.5.1 Diagnostic laboratories
- 5.11.5.2 Hospitals & clinics
- 5.11.5.3 Other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 NEXT-GENERATION SEQUENCING
- 6.1.2 POLYMERASE CHAIN REACTION
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS
- 6.2.2 LABORATORY INFORMATION SYSTEMS (LIS) & DIGITAL HEALTH INTEGRATION
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 CRISPR-BASED DIAGNOSTICS
- 6.3.2 DIGITAL PCR (DPCR)
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 LIST OF MAJOR PATENTS
- 6.6 FUTURE APPLICATIONS
- 6.7 IMPACT OF AI/GENERATIVE AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 TOP USE CASES & MARKET POTENTIAL
- 6.7.3 KEY COMPANIES IMPLEMENTING AI
- 6.7.4 FUTURE OF AI
7 SUSTAINABILITY & REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS & COMPLIANCE
- 7.1.1 REGULATORY ANALYSIS
- 7.1.1.1 North America
- 7.1.1.1.1 US
- 7.1.1.1.2 Canada
- 7.1.1.2 Europe
- 7.1.1.2.1 Germany
- 7.1.1.2.2 UK
- 7.1.1.2.3 France
- 7.1.1.2.4 Italy
- 7.1.1.3 Asia Pacific
- 7.1.1.3.1 China
- 7.1.1.3.2 Japan
- 7.1.1.3.3 India
- 7.1.1.3.4 Australia
- 7.1.1.4 Latin America
- 7.1.1.4.1 Brazil
- 7.1.1.4.2 Mexico
- 7.1.1.5 Middle East
- 7.1.1.5.1 Africa
- 7.1.1.1 North America
- 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.1 REGULATORY ANALYSIS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
- 7.2.1.1 Eco-friendly initiatives
- 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
- 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE
- 9.1 INTRODUCTION
- 9.2 REAGENTS & KITS
- 9.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH
- 9.3 INSTRUMENTS
- 9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH
- 9.4 SOFTWARE & SERVICES
- 9.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH
10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE
- 10.1 INTRODUCTION
- 10.2 MULTIPLEX TESTING
- 10.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH
- 10.3 SINGLEPLEX TESTING
- 10.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH
11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE
- 11.1 INTRODUCTION
- 11.2 LABORATORY TESTS
- 11.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH
- 11.3 POINT-OF-CARE TESTS
- 11.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET
12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE
- 12.1 INTRODUCTION
- 12.2 RESPIRATORY INFECTIOUS DISEASES
- 12.2.1 INFLUENZA
- 12.2.1.1 Growing focus on faster diagnosis and control to propel market
- 12.2.2 TUBERCULOSIS
- 12.2.2.1 Rise in undiagnosed and untreated cases to promote growth
- 12.2.3 PHARYNGITIS
- 12.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth
- 12.2.4 NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS
- 12.2.4.1 Increasing reliance on advanced molecular diagnostic technologies to fuel growth
- 12.2.5 OTHER RESPIRATORY INFECTIOUS DISEASES
- 12.2.1 INFLUENZA
- 12.3 GASTROINTESTINAL INFECTIOUS DISEASES
- 12.3.1 HEPATITIS
- 12.3.1.1 Rising global incidence of infections to expedite growth
- 12.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES
- 12.3.1 HEPATITIS
- 12.4 SEXUALLY TRANSMITTED DISEASES
- 12.4.1 HUMAN IMMUNODEFICIENCY VIRUS
- 12.4.1.1 Increasing number of blood transfusions and blood donations to augment growth
- 12.4.2 HUMAN PAPILLOMAVIRUS
- 12.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market
- 12.4.3 CHLAMYDIA TRACHOMATIS
- 12.4.3.1 Increasing incidence of chlamydia to aid growth
- 12.4.4 NEISSERIA GONORRHOEAE
- 12.4.4.1 Increasing development of novel assays to boost market
- 12.4.5 SYPHILIS
- 12.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
- 12.4.6 OTHER SEXUALLY TRANSMITTED DISEASES
- 12.4.1 HUMAN IMMUNODEFICIENCY VIRUS
- 12.5 HOSPITAL-ACQUIRED INFECTIONS
- 12.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET
- 12.6 VAGINITIS
- 12.6.1 INCREASING AWARENESS ABOUT WOMEN'S HEALTH TO BOLSTER GROWTH
- 12.7 MENINGITIS
- 12.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH
- 12.8 VECTOR-BORNE DISEASES
- 12.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET
- 12.9 BLOODSTREAM INFECTIONS & SEPSIS
- 12.9.1 HIGH BURDEN OF BLOODSTREAM INFECTIONS TO PROPEL MARKET
- 12.10 OTHER INFECTIOUS DISEASES
13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY
- 13.1 INTRODUCTION
- 13.2 POLYMERASE CHAIN REACTION
- 13.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
- 13.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
- 13.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH
- 13.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
- 13.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
- 13.5 IN SITU HYBRIDIZATION
- 13.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET
- 13.6 DNA MICROARRAYS
- 13.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH
- 13.7 OTHER TECHNOLOGIES
14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER
- 14.1 INTRODUCTION
- 14.2 DIAGNOSTIC LABORATORIES
- 14.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
- 14.3 HOSPITALS & CLINICS
- 14.3.1 RISING PATIENT VOLUMES TO CONTRIBUTE TO GROWTH
- 14.4 OTHER END USERS
15 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION
- 15.1 INTRODUCTION
- 15.2 NORTH AMERICA
- 15.2.1 US
- 15.2.1.1 Presence of advanced healthcare infrastructure to augment growth
- 15.2.2 CANADA
- 15.2.2.1 Favorable government initiatives to fuel market
- 15.2.1 US
- 15.3 EUROPE
- 15.3.1 GERMANY
- 15.3.1.1 Increasing healthcare expenditure to advance growth
- 15.3.2 UK
- 15.3.2.1 Growing number of diagnostic centers to fuel market
- 15.3.3 FRANCE
- 15.3.3.1 Increasing demand for early disease diagnosis to augment growth
- 15.3.4 ITALY
- 15.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market
- 15.3.5 RUSSIA
- 15.3.5.1 Increasing access to quality healthcare to facilitate growth
- 15.3.6 SPAIN
- 15.3.6.1 Growing public health initiatives to boost market
- 15.3.7 REST OF EUROPE
- 15.3.1 GERMANY
- 15.4 ASIA PACIFIC
- 15.4.1 CHINA
- 15.4.1.1 Rising public access to modern healthcare to spur growth
- 15.4.2 JAPAN
- 15.4.2.1 Universal healthcare reimbursement policy to foster growth
- 15.4.3 INDIA
- 15.4.3.1 Increased private and public investments to bolster growth
- 15.4.4 AUSTRALIA
- 15.4.4.1 Growing investments for testing centers and treatment facilities to drive market
- 15.4.5 REST OF ASIA PACIFIC
- 15.4.1 CHINA
- 15.5 LATIN AMERICA
- 15.5.1 BRAZIL
- 15.5.1.1 Growing focus on improving healthcare infrastructure to fuel market
- 15.5.2 MEXICO
- 15.5.2.1 Increasing accessibility and affordability of healthcare services to foster growth
- 15.5.3 REST OF LATIN AMERICA
- 15.5.1 BRAZIL
- 15.6 MIDDLE EAST & AFRICA
- 15.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
- 15.7 GCC COUNTRIES
- 15.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET
16 COMPETITIVE LANDSCAPE
- 16.1 INTRODUCTION
- 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 16.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- 16.3 REVENUE ANALYSIS, 2023-2025
- 16.4 MARKET SHARE ANALYSIS, 2025
- 16.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
- 16.4.2 US MARKET SHARE ANALYSIS, 2025
- 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 16.5.1 STARS
- 16.5.2 EMERGING LEADERS
- 16.5.3 PERVASIVE PLAYERS
- 16.5.4 PARTICIPANTS
- 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 16.5.5.1 Company footprint
- 16.5.5.2 Region footprint
- 16.5.5.3 Product & service footprint
- 16.5.5.4 Disease footprint
- 16.5.5.5 Test type footprint
- 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 16.6.1 PROGRESSIVE COMPANIES
- 16.6.2 RESPONSIVE COMPANIES
- 16.6.3 DYNAMIC COMPANIES
- 16.6.4 STARTING BLOCKS
- 16.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 16.6.5.1 Detailed list of key startups/SMEs
- 16.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
- 16.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
- 16.7 COMPANY VALUATION & FINANCIAL METRICS
- 16.7.1 FINANCIAL METRICS
- 16.7.2 COMPANY VALUATION
- 16.8 BRAND/PRODUCT COMPARISON
- 16.9 COMPETITIVE SCENARIO
- 16.9.1 PRODUCT LAUNCHES & APPROVALS
- 16.9.2 DEALS
- 16.9.3 EXPANSIONS
17 COMPANY PROFILES
- 17.1 KEY PLAYERS
- 17.1.1 DANAHER
- 17.1.1.1 Business overview
- 17.1.1.2 Products offered
- 17.1.1.3 Recent developments
- 17.1.1.3.1 Product approvals
- 17.1.1.3.2 Deals
- 17.1.1.4 MnM view
- 17.1.1.4.1 Key strengths
- 17.1.1.4.2 Strategic choices
- 17.1.1.4.3 Weaknesses & competitive threats
- 17.1.2 F. HOFFMANN-LA ROCHE LTD.
- 17.1.2.1 Business overview
- 17.1.2.2 Products offered
- 17.1.2.3 Recent developments
- 17.1.2.3.1 Product launches & approvals
- 17.1.2.3.2 Deals
- 17.1.2.3.3 Expansions
- 17.1.2.4 MnM view
- 17.1.2.4.1 Key strengths
- 17.1.2.4.2 Strategic choices
- 17.1.2.4.3 Weaknesses & competitive threats
- 17.1.3 BIOMERIEUX
- 17.1.3.1 Business overview
- 17.1.3.2 Products offered
- 17.1.3.3 Recent developments
- 17.1.3.3.1 Product launches & approvals
- 17.1.3.3.2 Deals
- 17.1.3.4 MnM view
- 17.1.3.4.1 Key strengths
- 17.1.3.4.2 Strategic choices
- 17.1.3.4.3 Weaknesses & competitive threats
- 17.1.4 HOLOGIC, INC.
- 17.1.4.1 Business overview
- 17.1.4.2 Products offered
- 17.1.4.3 Recent developments
- 17.1.4.3.1 Product approvals
- 17.1.4.4 MnM view
- 17.1.4.4.1 Key strengths
- 17.1.4.4.2 Strategic choices
- 17.1.4.4.3 Weaknesses & competitive threats
- 17.1.5 ABBOTT
- 17.1.5.1 Business overview
- 17.1.5.2 Products offered
- 17.1.5.3 Recent developments
- 17.1.5.3.1 Product approvals
- 17.1.5.3.2 Deals
- 17.1.5.4 MnM view
- 17.1.5.4.1 Key strengths
- 17.1.5.4.2 Strategic choices
- 17.1.5.4.3 Weaknesses & competitive threats
- 17.1.6 THERMO FISHER SCIENTIFIC INC.
- 17.1.6.1 Business overview
- 17.1.6.2 Products offered
- 17.1.6.3 Recent developments
- 17.1.6.3.1 Product launches
- 17.1.6.3.2 Deals
- 17.1.7 QIAGEN
- 17.1.7.1 Business overview
- 17.1.7.2 Products offered
- 17.1.7.3 Recent developments
- 17.1.7.3.1 Product launches & approvals
- 17.1.7.3.2 Deals
- 17.1.7.3.3 Expansions
- 17.1.8 REVVITY
- 17.1.8.1 Business overview
- 17.1.8.2 Products offered
- 17.1.9 GRIFOLS, S.A.
- 17.1.9.1 Business overview
- 17.1.9.2 Products offered
- 17.1.9.3 Recent developments
- 17.1.9.3.1 Product approvals
- 17.1.10 SEEGENE INC.
- 17.1.10.1 Business overview
- 17.1.10.2 Products offered
- 17.1.10.3 Recent developments
- 17.1.10.3.1 Product approvals
- 17.1.10.3.2 Deals
- 17.1.11 DIASORIN S.P.A.
- 17.1.11.1 Business overview
- 17.1.11.2 Products offered
- 17.1.11.3 Recent developments
- 17.1.11.3.1 Product approvals
- 17.1.11.3.2 Deals
- 17.1.12 SIEMENS HEALTHINEERS AG
- 17.1.12.1 Business overview
- 17.1.12.2 Products offered
- 17.1.12.3 Recent developments
- 17.1.12.3.1 Deals
- 17.1.12.3.2 Expansions
- 17.1.13 BECTON, DICKINSON AND COMPANY (BD)
- 17.1.13.1 Business overview
- 17.1.13.2 Products offered
- 17.1.13.3 Recent developments
- 17.1.13.3.1 Product approvals
- 17.1.13.3.2 Deals
- 17.1.13.3.3 Expansions
- 17.1.14 SD BIOSENSOR
- 17.1.14.1 Business overview
- 17.1.14.2 Products offered
- 17.1.14.3 Recent developments
- 17.1.14.3.1 Deals
- 17.1.1 DANAHER
- 17.2 OTHER PLAYERS
- 17.2.1 QUIDELORTHO CORPORATION
- 17.2.2 BRUKER
- 17.2.3 GENETIC SIGNATURES
- 17.2.4 CO-DIAGNOSTICS, INC.
- 17.2.5 VELA DIAGNOSTICS
- 17.2.6 MOLBIO DIAGNOSTICS PVT. LTD.
- 17.2.7 SAVYON DIAGNOSTICS
- 17.2.8 UNIOGEN OY
- 17.2.9 GENEOMBIO TECHNOLOGIES
- 17.2.10 ADVANCED MOLECULAR DIAGNOSTICS
- 17.2.11 ALTONA DIAGNOSTICS GMBH
- 17.2.12 GENEFIRST LIMITED
18 RESEARCH METHODOLOGY
- 18.1 RESEARCH DATA
- 18.2 SECONDARY DATA
- 18.2.1 LIST OF SECONDARY SOURCES
- 18.2.2 KEY DATA FROM SECONDARY SOURCES
- 18.2.3 PRIMARY DATA
- 18.2.3.1 List of primary sources
- 18.2.3.2 Key data from primary sources
- 18.2.3.3 Key industry insights
- 18.2.3.4 Breakdown of primary interviews
- 18.3 MARKET SIZE ESTIMATION
- 18.3.1 TOTAL MARKET SIZE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- 18.3.2 BOTTOM-UP APPROACH
- 18.3.2.1 Approach 1: Revenue estimation of key players
- 18.3.2.2 Approach 2: Study of annual reports and investor presentations
- 18.3.2.3 Approach 3: Primary interviews
- 18.3.2.4 Growth forecast
- 18.3.2.5 CAGR projections
- 18.3.3 TOP-DOWN APPROACH
- 18.4 DATA TRIANGULATION
- 18.5 RESEARCH ASSUMPTIONS
- 18.5.1 STUDY-RELATED ASSUMPTIONS
- 18.6 STUDY ASSUMPTIONS
- 18.6.1 PARAMETRIC ASSUMPTIONS
- 18.6.2 GROWTH RATE ASSUMPTIONS
- 18.7 RESEARCH LIMITATIONS
- 18.8 RISK ASSESSMENT
19 APPENDIX
- 19.1 DISCUSSION GUIDE
- 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 19.3 RELATED REPORTS
- 19.4 AUTHOR DETAILS
List of Tables
- TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES, 2010 VS. 2023 VS. 2024 (MILLION PEOPLE)
- TABLE 2 TOTAL TB INCIDENCE, 2024
- TABLE 3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
- TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
- TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS
- TABLE 6 EUROPE: MACROECONOMIC INDICATORS
- TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS
- TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS
- TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
- TABLE 10 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
- TABLE 11 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024-2026 (USD)
- TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
- TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
- TABLE 14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY CONFERENCES & EVENTS, 2026-2027
- TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES
- TABLE 16 KEY PATENTS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2022-2026
- TABLE 17 KEY COMPANIES IMPLEMENTING AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- TABLE 18 CLASSIFICATION OF IVD DEVICES IN EUROPE
- TABLE 19 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
- TABLE 20 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
- TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
- TABLE 27 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
- TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES
- TABLE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- TABLE 30 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 31 KEY REAGENTS & KITS AVAILABLE IN MARKET
- TABLE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 33 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 34 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 35 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 36 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 37 KEY INSTRUMENTS AVAILABLE IN MARKET
- TABLE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 39 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 40 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 41 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 42 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 43 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET
- TABLE 44 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 45 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 46 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 47 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 48 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 49 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 50 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 51 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 52 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 53 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 54 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 55 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 56 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 57 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 58 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 59 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 60 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 61 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 62 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 63 KEY LABORATORY-BASED TESTS AVAILABLE IN MARKET
- TABLE 64 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 65 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 66 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 67 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 68 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 69 KEY POINT-OF-CARE TESTS AVAILABLE IN MARKET
- TABLE 70 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 71 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 72 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 73 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 74 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 75 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 76 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 77 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 78 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 79 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 80 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 81 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 82 KEY INFLUENZA TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 83 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY REGION, 2024-2031 (USD MILLION)
- TABLE 84 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 85 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 86 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 87 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 88 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 89 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 90 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 91 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 92 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 93 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 94 KEY PHARYNGITIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 95 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 96 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 97 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 98 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 99 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 100 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 101 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 102 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 103 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 104 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 105 OTHER KEY RESPIRATORY INFECTION DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 106 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 107 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 108 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 109 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 110 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 111 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 112 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 113 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 114 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 115 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 116 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 117 KEY HEPATITIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 118 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 119 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 120 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 121 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 122 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 123 OTHER KEY GASTROINTESTINAL INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 124 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 125 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 126 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 127 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 128 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 129 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 130 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 131 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 132 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 133 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 134 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 135 KEY HIV TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 136 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY REGION, 2024-2031 (USD MILLION)
- TABLE 137 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 138 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 139 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 140 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 141 KEY HUMAN PAPILLOMAVIRUS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 142 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 143 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 144 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 145 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 146 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 147 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 148 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 149 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 150 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 151 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 152 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 153 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2024-2031 (USD MILLION)
- TABLE 154 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEA, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 155 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 156 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 157 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 158 KEY SYPHILIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 159 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 160 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 161 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 162 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 163 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 164 OTHER KEY SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 165 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 166 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 167 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 168 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 169 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 170 KEY HOSPITAL-ACQUIRED INFECTION TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 171 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 172 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 173 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 174 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 175 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 176 KEY VAGINITIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 177 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 178 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 179 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 180 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 181 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 182 KEY MENINGITIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 183 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 184 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 185 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 186 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 187 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 188 KEY VECTOR-BORNE DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 189 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 190 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 191 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 192 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 193 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 194 KEY BLOODSTREAM INFECTIONS & SEPSIS TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 195 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 196 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 197 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 198 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 199 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 200 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 201 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 202 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 203 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 204 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 205 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 206 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 207 KEY POLYMERASE CHAIN REACTION-BASED TESTS AND DEVICES AVAILABLE IN MARKET
- TABLE 208 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024-2031 (USD MILLION)
- TABLE 209 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 210 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 211 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 212 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 213 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED TESTS AND DEVICES AVAILABLE IN MARKET
- TABLE 214 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 215 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 216 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 217 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 218 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 219 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 220 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 221 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 222 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 223 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 224 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2024-2031 (USD MILLION)
- TABLE 225 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 226 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 227 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 228 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 229 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET
- TABLE 230 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 231 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 232 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 233 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 234 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 235 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 236 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 237 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 238 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 239 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 240 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 241 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 242 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 243 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 244 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 245 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 246 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 247 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 248 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 249 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 250 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 251 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 252 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 253 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 254 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 255 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 256 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 257 NORTH AMERICA: MACROECONOMIC INDICATORS
- TABLE 258 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 259 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 260 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 261 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 262 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 263 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 264 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 265 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 266 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 267 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 268 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 269 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 270 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 271 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 272 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 273 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 274 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 275 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 276 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 277 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 278 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 279 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 280 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 281 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 282 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 283 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 284 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 285 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 286 MACROECONOMIC INDICATORS FOR EUROPE
- TABLE 287 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 288 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 289 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 290 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 291 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 292 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 293 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 294 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 295 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 296 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 297 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 298 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 299 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 300 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 301 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 302 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 303 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 304 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 305 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 306 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 307 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 308 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 309 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 310 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 311 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 312 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 313 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 314 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 315 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 316 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 317 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 318 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 319 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 320 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 321 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 322 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 323 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 324 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 325 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 326 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 327 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 328 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 329 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 330 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 331 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 332 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 333 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 334 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 335 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 336 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 337 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 338 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 339 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 340 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 341 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 342 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 343 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 344 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 345 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 346 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 347 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 348 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 349 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 350 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 351 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 352 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 353 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 354 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 355 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 356 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 357 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 358 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 359 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 360 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
- TABLE 361 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 362 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 363 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 364 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 365 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 366 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 367 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 368 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 369 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 370 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 371 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 372 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 373 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 374 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 375 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 376 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 377 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 378 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 379 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 380 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 381 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 382 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 383 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 384 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 385 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 386 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 387 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 388 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 389 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 390 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 391 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 392 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 393 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 394 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 395 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 396 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 397 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 398 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 399 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 400 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 401 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 402 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 403 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 404 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 405 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 406 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 407 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 408 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 409 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 410 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 411 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 412 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 413 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 414 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 415 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 416 MACROECONOMIC INDICATORS FOR LATIN AMERICA
- TABLE 417 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 418 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 419 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 420 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 421 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 422 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 423 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 424 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 425 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 426 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 427 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 428 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 429 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 430 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 431 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 432 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 433 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 434 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 435 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 436 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 437 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 438 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 439 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 440 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 441 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 442 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 443 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 444 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 445 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 446 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 447 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 448 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 449 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 450 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 451 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 452 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 453 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 454 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 455 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 456 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 457 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 458 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 459 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 460 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 461 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 462 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 463 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
- TABLE 464 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 465 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
- TABLE 466 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024-2031 (USD MILLION)
- TABLE 467 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 468 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 469 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 470 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 471 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 472 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2023-APRIL 2026
- TABLE 473 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEGREE OF COMPETITION
- TABLE 474 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: REGION FOOTPRINT
- TABLE 475 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT
- TABLE 476 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DISEASE FOOTPRINT
- TABLE 477 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TEST TYPE FOOTPRINT
- TABLE 478 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
- TABLE 479 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
- TABLE 480 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
- TABLE 481 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 482 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEALS, JANUARY 2023-APRIL 2026
- TABLE 483 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: EXPANSIONS, JANUARY 2023-APRIL 2026
- TABLE 484 DANAHER: COMPANY OVERVIEW
- TABLE 485 DANAHER: PRODUCTS OFFERED
- TABLE 486 DANAHER: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 487 DANAHER: DEALS, JANUARY 2023-APRIL 2026
- TABLE 488 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
- TABLE 489 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
- TABLE 490 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 491 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023-APRIL 2026
- TABLE 492 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023-APRIL 2026
- TABLE 493 BIOMERIEUX: COMPANY OVERVIEW
- TABLE 494 BIOMERIEUX: PRODUCTS OFFERED
- TABLE 495 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 496 BIOMERIEUX: DEALS, JANUARY 2023-APRIL 2026
- TABLE 497 HOLOGIC, INC.: COMPANY OVERVIEW
- TABLE 498 HOLOGIC, INC.: PRODUCTS OFFERED
- TABLE 499 HOLOGIC, INC.: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 500 ABBOTT: COMPANY OVERVIEW
- TABLE 501 ABBOTT: PRODUCTS OFFERED
- TABLE 502 ABBOTT: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 503 ABBOTT: DEALS, JANUARY 2023-APRIL 2026
- TABLE 504 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
- TABLE 505 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
- TABLE 506 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023-APRIL 2026
- TABLE 507 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-APRIL 2026
- TABLE 508 QIAGEN: COMPANY OVERVIEW
- TABLE 509 QIAGEN : PRODUCTS OFFERED
- TABLE 510 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
- TABLE 511 QIAGEN: DEALS, JANUARY 2021-DECEMBER 2024
- TABLE 512 QIAGEN: EXPANSIONS, JANUARY 2021-DECEMBER 2024
- TABLE 513 REVVITY: COMPANY OVERVIEW
- TABLE 514 REVVITY: PRODUCTS OFFERED
- TABLE 515 GRIFOLS, S.A.: COMPANY OVERVIEW
- TABLE 516 GRIFOLS, S.A.: PRODUCTS OFFERED
- TABLE 517 GRIFOLS, S.A.: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 518 SEEGENE INC.: COMPANY OVERVIEW
- TABLE 519 SEEGENE INC.: PRODUCTS OFFERED
- TABLE 520 SEEGENE INC.: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 521 SEEGENE INC.: DEALS, JANUARY 2023-APRIL 2026
- TABLE 522 DIASORIN S.P.A.: COMPANY OVERVIEW
- TABLE 523 DIASORIN S.P.A.: PRODUCTS OFFERED
- TABLE 524 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 525 DIASORIN S.P.A.: DEALS, JANUARY 2023-APRIL 2026
- TABLE 526 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
- TABLE 527 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
- TABLE 528 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023-APRIL 2026
- TABLE 529 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023-APRIL 2026
- TABLE 530 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
- TABLE 531 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
- TABLE 532 BD: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
- TABLE 533 BD: DEALS, JANUARY 2023-APRIL 2026
- TABLE 534 BD: EXPANSIONS, JANUARY 2023-APRIL 2026
- TABLE 535 SD BIOSENSOR: COMPANY OVERVIEW
- TABLE 536 SD BIOSENSOR: PRODUCTS OFFERED
- TABLE 537 SD BIOSENSOR: DEALS, JANUARY 2023-APRIL 2026
- TABLE 538 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
- TABLE 539 BRUKER: COMPANY OVERVIEW
- TABLE 540 GENETIC SIGNATURES: COMPANY OVERVIEW
- TABLE 541 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
- TABLE 542 VELA DIAGNOSTICS: COMPANY OVERVIEW
- TABLE 543 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
- TABLE 544 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
- TABLE 545 UNIOGEN OY: COMPANY OVERVIEW
- TABLE 546 GENEOMBIO TECHNOLOGIES: COMPANY OVERVIEW
- TABLE 547 ADVANCED MOLECULAR DIAGNOSTICS: COMPANY OVERVIEW
- TABLE 548 ALTONA DIAGNOSTICS GMBH: COMPANY OVERVIEW
- TABLE 549 GENEFIRST LIMITED: COMPANY OVERVIEW
- TABLE 550 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RISK ASSESSMENT
List of Figures
- FIGURE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SEGMENTATION & REGIONAL SCOPE
- FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS
- FIGURE 3 GLOBAL MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2024-2031
- FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023-2025
- FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2025
- FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
- FIGURE 8 RISING CASES OF INFECTIOUS DISEASES TO DRIVE MARKET
- FIGURE 9 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
- FIGURE 10 MULTIPLEX TESTING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 11 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 12 STDS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
- FIGURE 16 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 17 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 18 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 19 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: VALUE CHAIN ANALYSIS
- FIGURE 20 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS
- FIGURE 21 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- FIGURE 23 PATENT ANALYSIS FOR MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2016-DECEMBER 2025
- FIGURE 24 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
- FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
- FIGURE 27 REGIONAL INCIDENCE OF HIV, 2023
- FIGURE 28 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT
- FIGURE 29 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT
- FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023-2025 (USD MILLION)
- FIGURE 31 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (GLOBAL)
- FIGURE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (US)
- FIGURE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
- FIGURE 34 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY FOOTPRINT
- FIGURE 35 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
- FIGURE 36 EV/EBITDA OF KEY VENDORS
- FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: BRAND/PRODUCT COMPARISON FOR MOLECULAR INFECTIOUS DISEASE TESTING
- FIGURE 39 DANAHER: COMPANY SNAPSHOT (2025)
- FIGURE 40 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
- FIGURE 41 BIOMERIEUX: COMPANY SNAPSHOT (2025)
- FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025)
- FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
- FIGURE 45 QIAGEN : COMPANY SNAPSHOT (2024)
- FIGURE 46 REVVITY: COMPANY SNAPSHOT (2025)
- FIGURE 47 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025)
- FIGURE 48 SEEGENE INC.: COMPANY SNAPSHOT (2025)
- FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
- FIGURE 50 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
- FIGURE 51 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025)
- FIGURE 52 SD BIOSENSOR: COMPANY SNAPSHOT (2024)
- FIGURE 53 RESEARCH DESIGN
- FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 55 TOP-DOWN APPROACH
- FIGURE 56 DATA TRIANGULATION
02-2729-4219
+886-2-2729-4219
2026年全球奈米抗體診斷市場報告
全球分子診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034）
感染疾病臨床檢查室分子診斷市場：按應用、地區和國家分類的策略、趨勢和預測 - 市場分析和管理指南（2026-2030 年）感染疾病分子診斷市場：按症候群、檢測項目、地點和國家分類－分析與執行指南（2026-2030 年）
分子診斷市場：2026-2032年全球市場預測（按產品、技術、檢體類型、檢測類型、應用和最終用戶分類）全球感染疾病分子診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034年）分子診斷市場自動化：按產品類型、技術、自動化程度、應用和最終用戶分類的全球市場預測，2026-2032 年
分子診斷原料市場規模、佔有率和成長分析：按產品類型、技術、應用、最終用戶和地區分類－2026-2033年產業預測2026年全球分子診斷設備與儀器市場報告2026年全球性行為感染傳染病分子診斷市場報告
▼